Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Pheochromocytoma/Paraganglioma
Status:
Recruiting
Trial end date:
2024-01-01
Target enrollment:
Participant gender:
Summary
Primary Objective:
To determine the response rate (RR) of metastatic or locally advanced
pheochromocytoma/paraganglioma to axitinib administered daily.
Secondary Objectives:
- Determine the progression-free survival.
- In an exploratory manner examine the extent of activation of the VEGFR pathway in
pheochromocytoma/paraganglioma using a semi-quantitative immunohistochemistry assay and
examine the relationship with response to therapy.
- Perform pharmacogenomics analyses of drug metabolism and transport proteins through
germline DNA examination.